In-Depth
View all In-depth content
![3D Isometric Flat Vector Conceptual Illustration of Biohazardous Medical Waste Disposal, Infectious Garbage Management](/sites/default/files/styles/homepage_large_article/public/2024-07/AdobeStock_516205346_resized.jpg.webp?itok=g57v18b8)
PharmEcology® is the exclusive company that can provide your organization with specialized solutions for USP 800 Assessment of Risk requirements and pharmaceutical waste management programs.
![Two doctors working in hospital pharmacy.](/sites/default/files/styles/homepage_sub_article/public/2024-07/AdobeStock_169615046._resized_0.jpg.webp?itok=IKFOrDfu)
It’s two o’clock in the morning when your phone rings. It’s the on-call hospital administrator at your facility. A natural disaster has struck, and your hospital must remain fully operational for the next 72-96 hours with limited external resources. The 96-hour emergency management plan at your hospital is being activated, and a media press conference is set to take place at 5:00 a.m.
![Pharmacy staff](/sites/default/files/styles/homepage_sub_article/public/2024-06/AdobeStock_169615127_resized.jpg.webp?itok=pyAJD4Tm)
Seven out of 10 pharmacies are understaffed1. When a pharmacy is understaffed, every aspect of the business suffers: employees become overburdened, lines are longer, and customer service deteriorates, resulting in patient and employee churn.
Does this situation sound familiar?
![Closeup pharmacist hand holding medicine box in pharmacy drugstore.](/sites/default/files/styles/homepage_sub_article/public/2024-07/AdobeStock_209236131_resized_0.jpg.webp?itok=mXewN1C-)
In a previous article, I covered 5 key things that hospital pharmacy leaders need to know about medication safety [SEE: '5 Things You Need to Know NOW About Medication Safety']. Now, we need to put this into action. In this article, I’ll touch on 4 things to jump start medication safety at your organization!
VIDEOS
VIEW ALL VIDEOS
Jennifer Matias, PharmD, BCPS, CPPS, who oversees medication safety for Kaiser Permanente's National Pharmacy Services, sat down with Pharmacy Angle to share her career journey, sparked by a near-miss medication error. Jennifer discusses the evolution of medication safety culture, the integration of technology, and the importance of proactive and reactive strategies to prevent errors. She also offers insights into current trends in hospital pharmacy, including the opioid crisis and process improvement initiatives.
Pharmacy Angle sat down with Ram Arumugam, Senior Manager of Product Management for McKesson Health to gain insights into his role, the evolving landscape of pharmacy operations, and the impact of DIR fee changes on the industry.
Pharmacy Angle meets with John Hamiel, Regional Director of Pharmacy at Mercy Health, to discuss changes he's see in the industry throughout his career and the role of AI in the future of hospital pharmacies.
Pharmacy Angle had the opportunity to interview Blake Powers, President at Medigi, discussing hot-button issues and how digitalization can benefit the pharmacy industry.
Industry News
View all Industry News
![Box and bottle of Brexpoprazole](/sites/default/files/styles/homepage_large_article/public/2024-07/Brexpiprazole_resized.jpg.webp?itok=7EKepn7J)
Princeton, NJ and Deerfield, IL — Otsuka Pharmaceutical, Co. Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) announce the U.S. Food and Drug Administration (FDA) has determined that the supplemental New Drug Application (sNDA) for brexpiprazole in combination with sertraline for the treatment of adults with post-traumatic stress disorder (PTSD) is sufficiently complete to permit a substantive review. The FDA has assigned the application for a Prescription Drug User Fee Act (PDUFA) target action date of February 8, 2025.
The sNDA submission is based on data from three randomized clinical trials evaluating the safety and efficacy of brexpiprazole in combination with sertraline in adult patients with PTSD.
The primary endpoint for all three trials was the change from randomization (Week 1) to Week 10 in the Clinician-Administered PTSD Scale (CAPS-5) total score for brexpiprazole and sertraline combination therapy versus sertraline plus placebo in patients diagnosed with PTSD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).
The trials were randomized, double blind, active-controlled, and Trial 061 (Phase II) and 071 (Phase III) were flexible dose trials, while Trial 072 (Phase III) was a fixed dose trial.1 In Trial 061 and 071, brexpiprazole in combination with sertraline was associated with a statistically significant reduction (p<0.05) in PTSD symptoms compared to sertraline plus placebo, as measured by the change in the CAPS-5 total score from randomization (Week 1) to Week 10 (primary endpoint). In Trial 072, while the primary endpoint was not met, reductions in PTSD symptoms with brexpiprazole in combination with sertraline were consistent with Trials 061 and 071. Improvements were consistently observed across the Clinical Global Impression Severity (CGI-S) scale and the four CAPS-5 clusters of re-experiencing, avoidance, negative cognition/mood and arousal/reactivity symptoms in Trials 061 and 071.
Across the three randomized trials, the combination of brexpiprazole and sertraline in adult patients with PTSD was generally well-tolerated, and no new safety observations were identified. The safety and tolerability results were consistent with the known profile of brexpiprazole in its approved indications and what has been observed in other clinical trials. The overall incidence of treatment-emergent adverse events (TEAEs) across the three trials was 55.5 percent with brexpiprazole plus sertraline, and 56.2 percent with sertraline plus placebo.2
“Post-traumatic stress disorder is one of the most common mental health disorders in the United States. Approximately 13 million adults in the U.S. have PTSD during a given year, and between seven to eight out of every 100 will experience PTSD at some point in their lives,” said John Kraus, M.D., Ph.D., executive vice president and chief medical officer, Otsuka. “This is a significant development, and we look forward to continuing our efforts to provide a treatment option that may benefit the millions of patients and caregivers who are impacted by the debilitating effects of PTSD.”
“Brexpiprazole in combination with sertraline could represent an important advancement over current standard of care, and we look forward to working with the FDA in the process of seeking approval of this combination,” said Johan Luthman, Ph.D., executive vice president, Lundbeck Research & Development. “We are grateful to the patients and caregivers who participated in these important trials.”
![Pharmacy, black man and woman with healthcare medicine and conversation for instructions.](/sites/default/files/styles/homepage_sub_article/public/2024-07/AdobeStock_560754118_resized.jpg.webp?itok=VFQl-Mvj)
Arlington, VA — Surescripts® released a new data report that highlights the biggest issues facing care providers, pharmacist prescribing trends and opportunities for patient care teams to continue evolving to meet the needs of patients.
![RxLink and ConnectiveRx logos](/sites/default/files/styles/homepage_sub_article/public/2024-07/Pharmacy%20Angle%20Industry%20News%20Image.jpg.webp?itok=rz2je5C_)
CHAPEL HILL, NC — RxLink™, a leading provider of medication affordability and price transparency solutions for healthcare systems, is excited to announce its strategic partnership with ConnectiveRx, a premier provider of patient support, affordability, awareness, and adherence solutions for branded and specialty prescription medications.
![Bottle of Eribulin Mesylate](/sites/default/files/styles/homepage_sub_article/public/2024-07/Pharmacy%20Angle%20Industry%20News%20Image%20%281%29.jpg.webp?itok=mx40hnbZ)
ROSEMONT, IL — Long Grove Pharmaceuticals, LLC, a supplier of differentiated pharmaceuticals, received Food and Drug Administration (FDA) approval for a generic Eribulin Mesylate Injection. Long Grove’s Eribulin Mesylate is an AP-rated chemotherapy medication bioequivalent to HALAVEN®.